Author(s):
Muzzi, Alessandro ; Brozzi, Alessandro ; Serino, Laura ; Bodini, Margherita ; Abad, Raquel ; Caugant, Dominique ; Comanducci, Maurizio ; Lemos, Ana Paula ; Gorla, Maria Cecilia ; Křížová, Pavla ; Mikula, Claudia ; Mulhall, Robert ; Nissen, Michael ; Nohynek, Hanna ; Simões, Maria João ; Skoczyńska, Anna ; Stefanelli, Paola ; Taha, Muhamed-Kheir ; Toropainen, Maija ; Tzanakaki, Georgina ; Vadivelu-Pechai, Kumaran ; Watson, Philip ; Vazquez, Julio A. ; Rajam, Gowrisankar ; Rappuoli, Rino ; Borrow, Ray ; Medini, Duccio
Date: 2019
Persistent ID: http://hdl.handle.net/10400.18/6634
Origin: Repositório Científico do Instituto Nacional de Saúde
Subject(s): 4CMenB Vaccine; Genotyping; Neisseria meningitidis Serogroup B; Strain Coverage; gMATS; Infecções Respiratórias
Description
Background: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine. Methods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%. Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates.
